Exxon Mobil enters its Q1 2026 earnings call on May 1 with short sellers cutting exposure, the Street raising targets, and the stock recovering ground after a bruising month — a setup where the risk is on the macro, not the positioning.
The most striking move of the week is the rapid unwind in short selling. Short interest fell 9% over the past seven days to just 1.02% of the free float — a level so modest it barely registers as a bearish signal. Back in mid-March, the equivalent figure was closer to 1.25% of float, and peak short-side positioning this year was well above that. Shorts have been a one-way trade since April 23, when shares briefly jumped above 46 million short before sellers stepped back. The borrow market confirms the absence of conviction: the cost to borrow is only 0.42% annualised, a near-trivial cost even after ticking up 14% over the week. Availability remains extremely loose, barely tightening from the very wide levels seen across March and April — every data point here says this is not a name where there is any meaningful short-side pressure.
Options carry the same calm tone. The put/call ratio is 0.64, almost exactly in line with its 20-day mean of 0.64, with a z-score that rounds to zero. There is no pronounced directional lean from derivatives desks heading into the print. The 52-week range for the PCR runs from 0.47 to 0.90, and the current level is almost perfectly mid-range — options traders are neither hedging hard nor pressing calls.
The Street has been more active. A flurry of analyst moves in April tells a consistent story: the direction of travel is upward on targets, with a few cautionary notes at the margin. Morgan Stanley trimmed its target by $1 to $171 on April 17 while keeping Overweight. The more notable move the same day came from BNP Paribas, which upgraded from Underperform to Neutral and lifted its target from $125 to $165 — an aggressive pivot. Scotiabank raised its target from $128 to $163 last week. The one genuine negative: Wolfe Research downgraded to Peer Perform on April 21, removing a prior Outperform rating with no new target. JP Morgan, by contrast, raised its target from $140 to $170 on April 9. The consensus mean target is $166.14, implying roughly 7% upside to Tuesday's close of $154.67. Analyst return potential is a modest 10%. The EV/EBITDA multiple has compressed about 12% over 30 days, to 7.7x — reflecting the oil price pressure rather than any deterioration in the underlying business. The P/E at 14.9x has also shed nearly 5 points over the same period. The dividend score ranks in the 97th percentile of the universe, consistent with XOM's reputation as a reliable income name, and forward yield is around 2.8%.
The fundamental picture into the quarter is mixed. Estimated Q1 revenue is roughly $85.3bn, with net income around $3.7bn and operating cash flow near $11.8bn — solid numbers, though chemicals margins remain under pressure. The bear case on the Street centres on exactly that: project execution risk on major capital commitments, chemicals weakness, and commodity price uncertainty. Bulls point to the portfolio breadth, the low oil price required to cover the dividend, and the company's history of outperforming on costs. EPS momentum is in the 75th–78th percentile over both 30- and 90-day windows, a signal that forward estimates are still moving in the right direction.
Among peers, CVX gained 1.9% on the day and 1.3% on the week — lagging XOM's 3.5% weekly recovery. OXY and DVN each outperformed more meaningfully, up 4% and 8.5% respectively over the week, suggesting the pure-play E&P names caught a stronger bid in the oil price bounce. XOM's more muted beta in both directions this month is typical of its integrated structure.
The last two earnings prints show a stock that doesn't move much at the open: Q1 2026 consensus revealed a 1-day move of -1.5% with a 5-day recovery of 6%, and an earlier print moved +3.5% on day one. The May 1 call is therefore less likely to be a volatility event than a margin and guidance read — the question is whether management updates its 2026 capex and cost-savings trajectory as commodity prices reset lower.
See the live data behind this article on ORTEX.
Open XOM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
